FDA Approves the First Blood Test that Detects Gene Mutation Linked to Non-small Cell Lung Cancer

The U.S Food and Drug Administration approved the blood based diagnostic of cobas EGFR Mutation Test v2 for Tarceva (erlotinib) cancer drug. It is the first blood test that will be able to detect a gene mutation, a leading breakthrough in the non-small cell lung cancer market, and a novel genetic test for detecting epidermal growth receptor gene mutation for relevant patients.

These mutations are affecting 10 to 20 percent of NSCLC, and a prime cause for cancer linked death in men more, but increasingly even women are dying due to related consequences. The test approved gives positive results, thus is it a great option for people who are unable to undergo examination of tumor specimen through EGFR testing. The efficacy of this test has had backing of clinical trials and determined safe.

Blood Sample Testing Helps Patients with NSCLC

NSCLC is among most common lung cancer type, which sheds tumor DNA in the patient’s blood, thus, making it possible for analyzing specific mutations via blood samples. Examining the tumor DNA blood is also known as liquid biopsy, whose approval can deliver individualized health care to people. These biopsies are potential in identifying patients with tumors specific mutation in most non-invasive way.

The cobas EGFR Mutation Test v2 detects NSCLC mutation specific presence in blood samples, assisting in selecting the ones that has benefits with treatment by Tarceva.  As per the medical market research, about 221,200 Americans may be diagnosed with lung cancer and the deaths will account for 158,040 people this year. The exon 21 substitution or exon 12 deletion mutations if not detected in person’s blood, can b studied via tumor biopsy then.

Tarceva as First-Line Treatment and Facts

FDA had given approval in 2004 for in treating patients with advanced locally or metastatic NSCLC following failure of a chemotherapy regimen. In 2013, the FDA certified the treatment as first-line in people with metastatic non-small cell lung cancer, with tumors of EGFR exon 19 deletions by an approved testing method. The common side effects for the treatment are anorexia, rash, fatigue, diarrhea, cough, dyspnea, vomiting, and nausea.

Tarceva is not for people who have taken a platinum underlined chemotherapy. It is not as first-line remedy for patients with NSCLC metastatic tumprs with EGFR mutations different than L858R substitution mutations or exon 19 deletions. The manufacturer of cobas EGFR Mutation Test v2 is Roche Molecular Systems in Pleasanton, California, while Tarceva is a brainchild of Astellas Pharma Technologies, Inc. of Norman, Oklahoma.

Healthcare Market Research Reports Study on Global Animal Medical Industry to 2020

The increase in consumption percentage for milk, pet adoption trend, rise in food borne and zoonotic diseases are the reasons why the global animal healthcare market is shifting ahead at a fast pace till 2020. As per the healthcare industry analysis, increasing income level of common man, population, and changing consumer prefer or lifestyle are some of leading factors to more consumption of meat across the world.

Given growing concerns for animal health and its rearing, expenses on farming technology, its methods are too being  studied intensively, as found by popular healthcare market research reports. Another aspect impending the industry’s expansion by 2020 is high demand for protein rich foods ilk meat, eggs, and milk for men, women, and even children. Greater numbers of people prefer lean meat for controlling weight.

Animal Husbandry and Derived Dietary Products

The animal husbandry market is categorized on pharmaceuticals, products, vaccines, and feed additives. As in medical market research, milk and meat are prime edibles in requirement. The production of animal population through artificial insemination or natural breeding has also become significant.

•     The pharmaceutical segment for the relevant sector is on rise given frequent occurrences of animal ailments, which upsurges concerns among owners to the pet and farm. The healthcare market research thus is also looking at initiatives from animal lovers and linked NGOs between 2015 and 2020.

•     Those who support animal rights and care for the beings are being encouraged to take protective measures for strays, and pets’ etc. regarding wellbeing. The private and government institutions have also stepped in to promote such cause, found in most of the healthcare industry analysis reports.

•     Modern genetic techniques for animal breeding are also now studied among scientists. Feed additives are being randomized to experiments in forecast period, noting the best edible for animals as per their breed and health.

Advancement of Global Animal Medical Care


There are several companies operating for animal healthcare market around the world, pioneering the industry. Some of such firms noted in healthcare market research reports are Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Zoetis Inc., Bayer AG, Vetoquinol S.A, Merial Limited, Elanco Animal Health Inc., Virbac SA, and Merck & Co. Inc. which are among the key players heading the markets.The market is also segmented on animal type, their companion, and levels of production. Consumption of animal protein is also growing as observed in medical market research. Thus producing quality meat and related products have become important for food and beverage industries.

Farm owners are given aids for upkeep of animal health, which includes vaccines, medicines, and timely care, as per the healthcare industry analysis till 2020 on global scenario. New ways are being studied on preventing or treating genetic mutations etc.

Global Prenatal and Maternal Diagnostic Market Sees CAGR 18% till 2020

The global prenatal and maternal diagnostic market includes a non-invasive series of prenatal screening tests. This industry will see a rise at CAGR 18% till 2020. In the prenatal diagnostic market, the expense is more in chorionic villus sampling, amniocentesis, and other surgical methods. The global maternal, prenatal, and newborn diagnostic screening test market will be worth more than $10.5 billion, which stands today at $8 billion. Maternal blood also reveals a lot about the woman’s and the unborn health.

Because of advanced genetic protocol and screening tests, it is possible to detect maternal complications or progress. Due to such steps, a lot many lives are saved. If treating an abnormal fetus growth or disease is needed, the diagnostics will aid doctors decide a treatment plan. Both the life expectancy of child and mother has improved with newer models in testing and analysis of diseases.

What are the Diagnostics in Prenatal Stage?

The platform is divided on fetal MRI, ultrasound, non-invasive screening technologies, maternal serum etc. These will have 4.1% growth rate in the next five years, as per medical market research. When DNA sequencing proved a success, the focus was shifted to treatment of genetic diseases. The need of remedies led to more experiments and advancements in pre-implantation genetic diagnosis, in vitro fertilization, fetal ultrasound tests, and modern prenatal tests etc.

How is Genetics Technology Helping Parents?

Intention behind such techniques is to detect genetic fault in fetuses, newborns, and embryos. The goal is to aid treatment of pregnancy disorders, structural chromosome diseases, numerical chromosome disorders, and single gene conditions inherited by the newborn, embryo or the fetus. The maternal diagnostic market is segregated as newborn screening, NIIPT, prenatal MRI etc. Emerging trends for relevant market is based on molecular diagnostics, in vitro techniques, liquid biopsy, and others.

Healthcare and Medical Market Research Throws Light on Pharma Expenditures

The cost to healthcare in the U.S. and other developed countries are on the rise. The total expenditure made by U.S. for 2015 in medical sector is approximately $3.24 trillion, which can grow to $3.78 trillion till 2018. In global scenario, the probable estimate spending is $6.7 trillion, as per healthcare market research reports.  Of the worldwide GDP, per capita splurging is around $921, with 8.3% stake for medical industry. U.S. itself captures $3.2 trillion.

 

New Direction of Medical Technology 

The technology on healthcare is being used for treatment, diagnosis, prevention of conditions and illnesses. Some of the advanced techniques involved are robotics, medical imaging, computer aided surgeries, portable analysis instrumentation. The way hospital administration is shaped and organized holds a key to better treatment options. As seen in most of the healthcare industry analysis, a lot many pharmaceuticals are depending on online advertising and marketing to promote their services.
 

Healthcare Sectors are soaking in Maximum Expenditures

Non American nations contribute $2.7 trillion followed by $0.8 trillion from few other parts of the world. Total prescription medicine market in 2015 for the globe was more than $1 trillion, and by 2018, the figures may reach $1.3 trillion. Even in remote regions, medical services are starkly increasing via telemedicine, more clinics established and online purchase of drugs.
 

• Cost to medication care is focused on physicians, hospitals, clinical services, prescription medicines, home health services, and nursing homes. According to the medical market research, the aid for health given to senior citizens have also boosted in numbers. By 2030, the numbers will account 82 million of aging population with medical aid.
 

• Child and parent care cost is also a high priority these day. Thus, life expectancy of people is improving given new and effective treatment options. Investments are high for invention and discovery of cures, especially in sector or serious illnesses like HIV/AIDS, cancer, and other terminal illnesses.